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Myeloﬁbrosis (MF) is a manifestation of several disorders of hematopoiesis, collectively referred to as
myeloproliferative neoplasms. Allogeneic hematopoietic stem cell transplantation (ASCT) is the only therapy
with proven curative potential. However, most patients with MF are in their 6th or 7th decade of life, and only
some of these patients have been considered suitable transplantation candidates. The development of
reduced-intensity conditioning regimens with limited toxicity has allowed clinicians to offer ASCT to a
growing number of older patients. The availability of Janus Kinase (JAK) 1/2 inhibitors allows clinicians to
provide symptom relief and improved quality of life for MF patients. These drugs may also affect the decision
regarding, in particular, the timing of ASCT. Future studies need to address the role of JAK1/2 inhibitors in
patients who are transplantation candidates and determine their role before and, possibly, after trans-
plantation. The identiﬁcation of indications for the use of JAK1/2 inhibitors in the context of transplantation
may lead to new therapeutic strategies for patients with MF.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION similar to that of PMF, PPV-MF and PET-MF represent distinct
Primary myeloﬁbrosis (PMF) is a myeloproliferative neo-
plasm (MPN) characterized by expansion of clonal hemato-
poietic cells and the release of cytokines that trigger the
development of marrow ﬁbrosis, neoangiogenesis, and osteo-
sclerosis. PMF manifests with blood cytopenias, leukoery-
throblastosis, extramedullary hematopoiesis, and progressive
splenomegaly that may be accompanied by hepatomegaly.
PMF is a rare disorder, with an estimated annual incidence of
approximately 1 per 100,000 and prevalence of 4 to 6 per
100,000 persons [1]. The disease primarily affects older in-
dividuals (median age at presentation, 67 years). The course of
the disease varies considerably, ranging from indolent, with
survival of more than a decade, to aggressive, with disabling
constitutional symptoms, impaired quality of life, cachexia,
and death within a year or 2 [2]. Myeloﬁbrosis (MF) can also
arise from polycythemia vera (PPV-MF) and essential throm-
bocythemia (PET-MF). Although the phenotypes may beedgments on page 1279.
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Conventional therapies, such as erythropoietin, andro-
gens, immunomodulatory drugs, interferon-alpha, cytore-
ductive agents, and nonpharmacological options, such as
blood transfusion, spleen irradiation, and splenectomy, have
not signiﬁcantly prolonged patient survival. Allogeneic stem
cell transplantation (ASCT) is the only currently available
therapy with curative potential for MF [4]. However, because
MF mainly affects older individuals, most MF patients have
traditionally not been considered for ASCT. With the more
recent adoption of reduced-intensity conditioning (RIC) re-
gimens, ASCT has become applicable to a larger proportion
of patients with MF [5-9]. However, in older individuals,
comorbidities (related or unrelated to MF) are common and
may create challenges even with RIC, further affecting pa-
tient selection for ASCT, transplantation timing, and condi-
tioning strategy [10,11]. Data on how the use of Janus Kinase
(JAK) 1/2 inhibitors will impact transplantation outcomes are
only beginning to emerge [12-14].
RISK-SCORING AND PATIENT SELECTION
Therapeutic decisions surrounding ASCT for MF require
a risk-adapted approach. The Lille score, based on hemoglobinTransplantation.
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risk-adapted therapy, suggesting that ASCT should be con-
sidered with intermediate- or higher risk disease (1 or 2 risk
factors) [15]. More recently, new scoring systems have been
developed.
The International Prognostic Scoring System (IPSS) esti-
mates the expected survival from the time of MF diagnosis
based on 5 risk factors [16]: (1) age > 65 years, (2) hemo-
globin < 100 g/L, (3) leukocyte count > 25  109/L, (4)
circulating myeloblasts  1%, and (5) presence of constitu-
tional symptoms.
In the IPSS, patients are classiﬁed as low risk (score ¼ 0,
median survival of 135 months), intermediate-1 risk
(score ¼ 1, median survival of 95 months), intermediate-2
risk (score ¼ 2, median survival of 48 months), or high risk
(score  3, median survival of 27 months) [16]. A dynamic
IPSS (DIPSS) score, proposed subsequently, uses the same 5
risk factors but allows for prognostic prediction at any time
during the disease course. Under the DIPSS, hemoglobin
concentration <100 g/L received a score of 2 points; the
overall classiﬁcation is as follows [17]: low risk is indicated
by a score of 0; intermediate-1 risk, score of 1 or 2;
intermediate-2 risk, score of 3 or 4; and high risk, score of 5
or 6.
The DIPSS has been further reﬁned as DIPSS Plus, which
adds 3 additional risk factorsdtransfusion dependence, un-
favorable karyotype, and platelet count < 100  109/Ldeach
assigned a 1-point score [18]. All of these scoring systems
were based on studies in patients with PMF only and were
developed before the wider availability of JAK inhibitors.
Further reﬁnement of risk stratiﬁcation systems is ex-
pected by integrating somatic mutations in the models. One
recent study has shown ASXL1, SRSF2, IDH1/2, and EZH2
mutations to be independently associated with poor survival
[19]. Using the mutation information of these 4 genes, a
follow-up study by the same investigators showed that the
hazard ratios for survival were 2.78 and 1.52 for patients who
had  2 mutations or 1 mutation, respectively, compared
with patients without mutations [20]. Recently, additional
mutations involving the calreticulin (CALR) gene have been
described in patients with PMF and essential thrombocy-
themia [21,22]. CALR mutations were mutually exclusive
from mutations in JAK2. The data suggest that patients with
PMF who harbor a CALR mutation have superior survival
compared with those with a JAK2 mutation [21]. It is not
known at present how the presence of ASLX1, SRSF2, IDH1/2,
and EZH2 mutations in CALR-positive patients may affect
prognosis.FACTORS AFFECTING TRANSPLANTATION PROGNOSIS
Additional factors that may affect outcomes after ASCT
include the presence of comorbidities, stem cell donor type,
and conditioning regimen [2,11,23-25]. Because patient
comorbidities weigh heavily in transplantation decisions,
additional (not disease-speciﬁc) scoring systems have been
developed, in particular the Hematopoietic Cell Trans-
plantation Comorbidity Index (HCT-CI). This index assigns
weighted scores to particular medical conditions that affect
nonrelapse mortality and survival. The highest scores are
assigned to heart valve disease, severely impaired pulmo-
nary function, moderate-to-severe hepatic disease, and a
history of a solid tumor malignancy [23]. Although a formal
validation in MF patients is pending, 2 recent analyses of
transplantation results in patients with MF showed aninverse correlation of HCT-CI scores and transplantation
success [26,27].
The prognostic value of the Lille scoring system has been
studied extensively in hematopoietic cell transplantation
(HCT) recipients [1,4]. Although patients with low-risk dis-
ease have better outcomes compared with those of inter-
mediate- and high-risk patients, these patients are generally
not considered candidates for transplantation, as their sur-
vival with supportive therapy alone is usually good. Relapse
incidence appears to be higher in patients with high Lille
scores [11]. Studies on the use of new scoring systems in
predicting outcomes after HCT have not shown consistent
results. Two studies reported that post-HCT success was
dependent on pre-HCT DIPSS scores [26,27]; a large pro-
portion of those patients received high-intensity (myeloa-
blative) conditioning. Two large studies from the European
Group for Blood and Marrow Transplantation and the Center
for International Blood and Marrow Transplant Research
(CIBMTR), focusing mainly on RIC, reported that DIPSS,
although predictive, did not sufﬁciently differentiate be-
tween intermediate-1 and intermediate-2 risk populations
[9,28].
It has been controversial whether splenectomy before
transplantation is associated with better outcomes, although
several studies have shown that hematopoietic recovery
is faster in splenectomized patients. A recent study from
the CIBMTR failed to show any impact of splenectomy or
splenic radiation on graft-versus-host disease (GVHD) or
survival in patients with myeloid malignancies, including
myeloﬁbrosis [29].
THE CHALLENGE OF ADVANCED AGE AND ASCT
One important factor in the decision-making process
about transplantation is the advanced age of many patients
with MF [2]. One retrospective study analyzed the results of
ASCT in 30 patients, ages 60 to 78 years, with PMF, PPV-MF,
or PET-MF, some with high HCT-CI scores [7]. Donors were
human leukocyte antigen (HLA)eidentical siblings or unre-
lated, and conditioning regimens ranged from very low
(ﬂudarabine plus 2 Gy total body irradiation) to high in-
tensity (high-dose busulfan plus cyclophosphamide). With a
median follow-up of 22 months, 3-year overall survival and
progression-free survival were projected to be 45% and 40%,
respectively. These results suggested that selected older
patients with advanced MF can be treated successfully with
ASCT.
ASCT AND DONOR SOURCES
Only 25% to 30% of patients have an HLA-identical sibling,
and increasing numbers of transplantations are carried out
from unrelated donors (URD). Transplantations from HLA-
mismatched related (haploidentical) donors or with umbil-
ical cord blood (UCB) are also being explored in MF [30,31].
Several studies have reported results with URDs to be similar
to those with HLA-identical siblings (outcomes with HLA-
mismatched donors were inferior) [4,32]. However, data
from the CIBMTR, showed a 1-year nonrelapse mortality of
27% for transplants from related donors and 43% for URD
ASCT [33]. These data were conﬁrmed by a recent update
from the CIBMTR that showed adjusted probabilities of 5-
year survival for matched sibling donors, well-matched
URDs, and partially matched URDs after RIC of 56%, 48%,
and 34%, respectively [9].
The Italian registry also showed lower transplantation-
related mortality (TRM) with transplantations from related
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de Greffe de Moelle et de Thérapie Cellulaire showed a lower
probability of engraftment and survival with nonsibling do-
nors compared with HLA-matched siblings [35]. Differences
in results between these studies could be attributable to
small sample sizes, their retrospective nature, patient and
disease heterogeneity, and the different regimens utilized for
transplantation. In a prospective trial of RIC-ASCT in 66 pa-
tients, 78% of patients who underwent transplantation from
related donors, compared with 44% of patients who under-
went transplantation from URDs, survived at a median
follow-up of 24 months [24]. Data with HLA-haploidentical
transplantations in MF are too limited for a detailed analysis.
DISEASE RISK AND PATIENT SELECTION
Recommendations for ASCT in MPNs are to offer trans-
plantation to eligible patients with life expectancy of
< 5 years. Patients in IPSS or DIPSS intermediate-2 and high-
risk categories should be considered for ASCT, as should be
those with DIPSS-weighted RBC-transfusion dependence or
unfavorable cytogenetics [2,24]. An algorithm for ASCT is
shown in Figure 1. However, there are patients, particularly
of younger age, who do not fall into higher risk categories
(eg, who may have intermediate-1 risk disease) but deserve
to be considered for transplantation.
POST-TRANSPLANTATION PROBLEMSWITH ASCT FORMF
Regimen-related Toxicities
PatientswithMFare at risk for liver injury, probably related
to liver involvement by their disease (ie, intrasinusoidal
hematopoiesis, ﬁbrosis, portal hypertension) [36]. One study
showed signiﬁcantly higher risks of post-transplantation
moderate/severe hyperbilirubinemia and veno-occlusive dis-
ease (sinusoidal obstruction syndrome) than seen, for
example, in patients with myelodysplastic syndrome [36].
Signiﬁcant hyperbilirubinemia is associated with inferior
survival. The incidence of hepatotoxicity has declined steeply
in recent years, presumably related to the prophylactic use of
ursodiol and novel conditioning regimens [37]. Patients withFigure 1. Algorithm for hematopoietic cell transplantation in patients with MF based o
(in addition to karyotype and red cell transfusion dependence), also affects prognosis
regimen remains a matter of controversy. As discussed in the text, the ways in which th
yet to be determined.MFmay also be at risk of increased pulmonary complications
due to extramedullary hematopoiesis in the lungs.
Graft Failure
The incidence of graft failure in patients withMF has been
reported at 2% to 25% [11,24]. In 2 prospective studies, the
graft failure rate was 2% in patients conditioned with a
combination of ﬂudarabine, busulfan, and antithymocyte
globulin (ATG) [11] and, in a study from the Myeloprolifer-
ative Diseases Research Consortium, 30% (primary or sec-
ondary graft failure) after URD ASCT and conditioning
with ﬂudarabine, melphalan, and ATG [24]. In a CIBMTR
analysis, day 100 TRM was 18% with HLA-matched related,
35% with unrelated, and 19% with HLA-nonidentical related
donors [33].
The actual risk factors for graft failure are poorly under-
stood and need further study [5]. It is currently not clear
whether strategies such as the use of T celledepleting ther-
apies with ATG will reduce the risk of graft failure. As indi-
cated earlier, a low risk of graft failure was seen in the
German study using Fresenius ATG (Bad Homburg, Germany)
as part of the conditioning protocol. However, the risk of
graft failure was high with unrelated donor transplantation
in the Myeloproliferative Diseases Research Consortium
study, which used the thymoglobulin preparation in the
conditioning protocol. Most transplantation physicians use
mobilized peripheral blood stem cells as the preferred graft
source for MF, although no formal comparison on the impact
of various graft sources on outcome in MF has been pre-
sented. It is notable that a recent prospective trial in patients
with MF, using conditioning with cyclophosphamide fol-
lowed by busulfan observed no graft failure [38].
GVHD
GVHD remains the most frequent complication of ASCT
[5]. Data from the CIBMTR showgrades II to IV acute GVHD in
43% of patients who underwent transplantation from HLA-
matched related donors, 40% from URDs, and 24% from
HLA-nonidentical related donors [30]. The incidence ofn DIPSS score. Platelet count, another parameter of the DIPSS Plus classiﬁcation
, with and without HCT. The selection of the intensity of the HCT conditioning
e availability and use of JAK inhibitors will modify the decision about HCT have
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tensity [39]. In 1 study, the rate of acute GVHD was signiﬁ-
cantly lower with RIC than with high-intensity conditioning
(18% versus 78%, respectively) [39]. Inﬂammatory cytokines,
which are constitutively dysregulated in MF, and are addi-
tionally released from injured tissue after transplantation




Early studies of ASCT for MF used myeloablative condi-
tioning involving total body irradiation or high-dose busulfan
[41]. The introduction of “targeted” busulfan (adjusting doses
to predetermined plasma levels) reduced toxicity and
improved survival [4]. However, these regimens have gener-
ally not beenused in older patients, forwhomRIC has become
the standard approach [34]. RIC regimens have mostly been
ﬂudarabine based and shown tobemore immunosuppressive
than myelosuppresive [42,43].
An analysis of a CIBMTR cohort of 60 patients prepared
with RIC regimens showed TRM of 15%. Relapse-free survival
was 39% [30]. However, there is currently no consensus on
the use of RIC. In an analysis by the Italian transplantation
group, conditioning intensity did not have an important in-
ﬂuence on outcomes, possibly related to the heterogeneity of
drugs used within the trials. However, RIC was associated
with a higher rate of graft failure compared with myeloa-
blative regimens [34,44].
Although RIC regimens have played an important role in
increasing the availability of ASCT and have been associated
with reduced TRM, further studies are required to assess
their relationship to improved overall survival [5,30]. One
such randomized trial, BMT CTN 0901, which is comparing
high-intensity conditioning with RIC, is currently ongoing in
the United States in patients with acute myeloid leukemia or
myelodysplastic syndrome [45].
JAK1/2 INHIBITORS IN MYELOFIBROSIS: UPDATE ON
CLINICAL TRIALS
Ruxolitinib
Aberrant JAK activation is seen in the majority of patients
with MF, regardless of JAK2 (V617F) mutation. JAK inhibitors
are compounds developed over the past decade for the
treatment of MPNs and other conditions [2]. Ruxolitinib
is the ﬁrst JAK inhibitor approved by the US Food and
Drug Administration for patients with intermediate- or high-
risk MF (primary MF, PPV-MF, or PET-MF) [46-51]. It is
approved in Europe for MF patients with symptomatic
splenomegaly, regardless of IPSS risk classiﬁcation. Rux-
olitinib, a JAK1/JAK2 inhibitor, showed early clinical beneﬁts
in patients with intermediate-2 and high risk MF, including
reductions in spleen size and improvements in debilitating
constitutional symptoms in a phase I/II (INCB18424-251) and
in the phase III COMFORT-I and COMFORT-II trials [46,50,51].
Analyses of both the COMFORT-I (ruxolitinib versus placebo)
and COMFORT-II (ruxolitinib versus best available care) trials
showed a survival beneﬁt for patients treated with rux-
olitinib [50,51].
In the original INCB18424-251 study of 107 patients with
intermediate-2 or high-risk MF, 54% of patients still received
ruxolitinib after a follow-up of 32 months, and survival
was 69%. Reduction of splenomegaly and improvement of
constitutional symptoms were sustained. Ruxolitinib was
well tolerated, with cumulative discontinuation rates of 24%,36%, and 46%, at 1, 2, and 3 years, respectively. Survival
was signiﬁcantly superior among patients treated with rux-
olitinib than among 310 matched controls, mainly attribut-
able to a highly signiﬁcant difference in the high-risk group
(P ¼ .006). Patients with  50% spleen size reduction sur-
vived longer than patients with < 25% reduction. These data
suggest that long-term ruxolitinib therapy may alter the
natural course of the disease, though longer follow-up is
needed to conclusively determine this effect [46].
Fedratinib
Fedratinib (SAR302503 or TG101348) is a selective JAK2
inhibitor. In a phase I trial in intermediate- and high-risk
patients with PMF or PPV MF/PET MF, fedratinib substan-
tially relieved constitutional symptoms. After 6 to 12 cycles,
a signiﬁcant proportion of patients achieved spleen size re-
ductions of 39% and 47%, respectively, and most patients
with leukocytosis or thrombocytosis normalized blood cell
counts. Side effects included anemia, nausea, and diarrhea. A
decrease in JAK2 V617F allele burden observed at 6months in
mutation-carrying patients persisted after 12 months [52].
Results of a phase III study with this compound were also
encouraging; however, further development of fedratinib
has been stopped because of several cases of a syndrome
resembling Wernicke encephalopathy [53].
SB1518/Pacritinib
In a phase I/II trial of pacritinib, another oral JAK2 inhib-
itor, in 21 patients, spleen size reduction of 50% occurred in
5 (24%), and a reduction of  35% in 9 (41%) [54]. A second
study in 34 patients showed decreases in spleen size of
 50% in 15 patients (44%), with 6 patients (18%) achieving
complete clinical normalization. Constitutional symptoms
were also reduced signiﬁcantly. Myelosuppression was
minimal, and the only relevant side effects were gastroin-
testinal (diarrhea) [54]. Pacritinib is being evaluated in 2
phase III trials, PERSIST-I and -II [55].
Momelotinib
Momelotinib (CYT387) is yet another potent inhibitor of
JAK 1/2. Results from a phase I/II multicenter study showed
reduction of splenomegaly and constitutional symptoms, as
well as reduced red cell transfusion requirements [56]. In a
longer-term phase I/II trial in 60 patients, anemia and spleen
response rates were 59% and 48%, respectively, and 70% of
transfusion-dependent patients achieved transfusion inde-
pendence of  12 weeks. In addition, 50% of patients had a
decrease in spleen size of 50%, whereas 17% had a complete
normalization. Substantial improvements were also seen in
constitutional symptoms [57]. However, the true beneﬁt
was not clear in the absence of a control arm. Momelotinib
will be compared with ruxolitinib in an upcoming phase III
randomized study.
Several other JAK inhibitors (LY2784544, BMS911543, NS-
018, and INCB-39110) are in various stages of clinical devel-
opment [58].
Disease Persistence with JAK2 Inhibitor Therapy
Although JAK2 inhibitors improve MPN-associated
splenomegaly and constitutional symptoms, they do not
eliminate the MPN clone, and, in most patients, neither
substantial reduction of JAK2 V617F allele burden nor
marrow ﬁbrosis has been observed. JAK inhibitors are not
speciﬁc for the JAK2 V617F mutation; they likely control MF-
related signs and symptoms via inhibition of the JAK-STAT
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This probably involves the reactivation of JAK-STAT signaling
via heterodimerization between activated JAK1 and JAK2 or
TYK2. This phenomenon is reversible, as demonstrated in
cell lines, animal models, and patients treated with JAK2
inhibitors. Therapies that result in JAK2 degradation retain
efﬁcacy in persistent cells and may provide additional ben-
eﬁts in patients previously treated with JAK2 inhibitors [59].
DEFINING THE ROLE OF JAK INHIBITORS IN ASCT
What Have We Learned from ASCT for Chronic Myeloid
Leukemia in the Era of Tyrosine Kinase Inhibitors?
The arrival of the tyrosine kinase inhibitor (TKI) imatinib
caused a dramatic change in the therapy of chronic phase
chronic myeloid leukemia (CML). Before imatinib, the only
curative therapy for CML was ASCT. Since the introduction of
imatinib (and other TKIs), TKI therapy has replaced ASCT as
front-line therapy for CML [60]. The original 5-year ran-
domized study comparing imatinib with standard combi-
nation therapy with cytarabine and interferon a showed
complete cytogenetic responses in 69% of imatinib-treated
patients by 12 months and 87% by 60 months; only 7% of
patients progressed to accelerated/blast phase [61]. The
second generation TKIs, nilotinib and dasatinib, show even
greater short-term potency [62-64].
Although ASCT remains an important option for the
management of CML, the number of ASCTs performed for
CML has decreased signiﬁcantly with the arrival of TKI
therapy [60,65]. National Cancer Center Network and the
European Leukemia Net CML guidelines promote ASCT in
chronic phase disease only when patients are intolerant or
resistant to all available TKIs, and for progression to accel-
erated/blast phase [66,67].
Major lessons from CML that may be relevant to MF are as
follows: (1) When new, effective therapy is available, treat-
ment patterns may shift radically; (2) As this happens, the
prevalence of disease will dramatically increase (because
prevalence equals incidence multiplied by duration of dis-
ease); and (3) Many studies showed that treating CML pa-
tients with imatinib before transplantation did not affect
transplantation outcomes [68]. Similar studies will need to
be performed inMF patients to assure that the policy of using
JAK inhibitors as a bridge (or even, a wall) to transplantation
does not “boomerang” and ultimately interfere with favor-
able patient outcomes.
It is important to note, however, that, although CML and
MF are both categorized as MPNs, the biology of MF is
considerably more complex than CML. Although JAK 1/2 in-
hibitors have salutary effects by decreasing the symptom
burden in patients with MF, they are not comparable to BCR-
ABL inhibitors. Reduction in JAK2 allele burden (a surrogate
marker for the malignant clone) is modest with JAK 1/2 in-
hibitors, and the rates of discontinuation of JAK inhibitor
therapy are much higher than observed with BCR-ABL in-
hibitors. An extended follow-up of the COMFORT-1 trial has
shown that rates of discontinuation of ruxolitinib were 21%,
35%, and 51% at 1, 2, and 3 years, respectively [69]. Moreover,
JAK inhibitor therapy is not known to reduce the risk of
leukemic transformation.
The Impact of the JAK Mutation on ASCT
The impact of the JAK mutation JAK2 (V617F) on ASCT
outcomes is still uncertain, although it is present in 50%
of patients with PMF, almost all patients with PPV-MF, and
40%-50% of patients with PET-MF. This mutation can serve,however, as a marker for residual or recurrent disease after
ASCT. One study evaluated 139 of 162 patients with known
JAK2 V617F mutation status after ASCT after RIC to assess
the impact of JAK2 V617F allele burden and clearance on
transplantation outcome. After a median follow-up of
19 months, patients with the JAK2 V617F mutation showed
superior survival (70% versus 44% for those with wild-type
JAK2). JAK2 V617F negativity was associated with signiﬁ-
cantly reduced incidence of relapse [70]. However, this was
not conﬁrmed in a second study, which showed a lower
probability of long-term survival in patients with the muta-
tion [26]. Thus, further investigations are needed to assess
the impact of JAK2 V617F status and allele burden on trans-
plantation outcomes. In addition, studies will be required to
understand how transplantation can modify the negative
prognostic impact of ASLX1, SRSF2, IDH1/2, and EZH2
mutations.
The Potential Risks and Beneﬁts of JAK1/2 Inhibitors
in ASCT
The beneﬁts of JAK2 inhibitors recognized so far include
lowering of symptom burden by reducing splenomegaly and
constitutional symptoms. JAK1/2 inhibitors may serve as an
alternative to splenectomy in patients with signiﬁcant
splenomegaly as surgical splenectomy is associated with a
high risk of perioperative complications (27.7%) and mor-
tality (6% to 7%), and is not routinely recommended before
ASCT [5]. Although a survival beneﬁt has been observed in
some trials with the use of JAK1/2 inhibitors, these survival
beneﬁt data must be conﬁrmed in long-term follow-up
studies and across the class of these drugs. JAK1/2 inhibitors
reduce proinﬂammatory and proangiogenic cytokines, but
they have limited effects on marrow ﬁbrosis, cytogenetic
abnormalities, and leukemic transformation. MF-associated
symptoms may also quickly return after discontinuation of
therapy [5]. Preliminary data suggest that the sequential use
of JAK inhibitors before ASCT and ATG in the conditioning
regimen may reduce the risk of GVHD, and, possibly, the
incidence of rejection; however, patients will need to be
monitored for infections and the graft-versus-leukemia ef-
fect. The effect of JAK inhibition on bone marrow ﬁbrosis is a
focus of current investigations [71,72].
As discussed for CML, it is likely that the commercial
availability of JAK1/2 inhibitors will affect referral patterns
for ASCT; it is currently not know whether this will affect
outcomes after ASCT. Patients with clinically relevant re-
sponses to JAK1/2 inhibitors may delay a decision about
transplantation and may have more advanced disease once
referred for ASCT. One potential advantage of JAK1/2 in-
hibitors, in addition to decreasing constitutional symptoms,
is the reduction of splenomegaly, which may hasten hema-
tologic recovery after ASCT. Further, the downregulation
of inﬂammatory cytokines might favorably impact GVHD
and, possibly, graft failure. This would be attractive, as MF-
associated symptoms are thought to be a risk factor for
outcome after ASCT [30]. However, only prospective trials
can deﬁnitively address this question.
Clearly, data on the use of JAK1/2 inhibitors in the setting
of transplantation are just beginning to emerge. A positive
impact of the use of ruxolitinib before transplantation was
recently suggested by 2 small retrospective studies from
Germany [12,73]. Of particular note, a signiﬁcant improve-
ment in performance status was observed with the use of
ruxolitinib in patients who were not initially considered
suitable candidates for transplantation [12]. A second study
Table 1
Case 1
A 68-year-old female was initially diagnosed with polycythemia vera in
2001 and initially treated with intermittent phlebotomy, low-dose
aspirin, and hydroxyurea. Her need for phlebotomy decreased in
2008 and was no longer required after 2009. In January 2012, she
presented with abdominal fullness, decreased appetite, marked
fatigue and a weight loss of 10 kg.
Her Eastern Cooperative Oncology Group performance score was 2; the
spleen was palpable by 20 cm below the left costal margin. The
hemoglobin was 96 g/L, WBC 26  109/L, and platelets 300  109/L.
The differential count showed left shift, nucleated red cells and 2%
myeloblasts. Her lactate dehydrogenase was 985 U/L (upper limit of
normal, 240).
A bonemarrow biopsy showed grade 3/3 ﬁbrosis,< 5%myeloblasts, and
normal cytogenetics. Cells expressed the JAK2 V617F mutation. The
patient has 2 healthy siblings, ages 64 and 66 years.
Question 1: How would you treat this patient?
 Wait and watch
 Continue hydroxyurea
 Immediate allogeneic transplantation if a suitable donor identiﬁed
 JAK1/2 inhibitor therapy with transplantation only if JAK inhibitor
therapy fails
 JAK1/2 inhibitor therapy with transplantation as soon as spleen size
has been reduced
Discussion: The patient’s physician started her on the JAK1/2 inhibitor
ruxolitinib, and after 6 weeks, she had signiﬁcant improvement in
symptoms. Her blood counts were stable, and she was transfusion
independent. HLA typing, meanwhile, shows 1 of her siblings to be
HLA-identical.
Question 2: What would you recommend at this point?
 Proceed with allogeneic transplantation from her sibling donor
 Continue ruxolitinib; no need for transplantation.
 Other options
Discussion: This patient had a gratifying response to JAK1/2 inhibition.
As a 68-year-old patient, transplantation would, presumably, involve
a RIC regimen. Although some data suggest a higher probability of
relapse with RIC than observed with high-intensity conditioning,
other reports have shown low relapse rates. Although there is a 50%
to 60% probability of long-term survival and remission, there is also
approximately a 50% chance of developing GVHD requiring therapy,
possibly long-term. Thus, with the present state of knowledge, it is
difﬁcult to provide an absolutely deﬁnitive recommendation. Some
patients might prefer conservative management with continuation of
ruxolitinib until there are signs of disease acceleration/progression.
Other patients (and physicians) might prefer to proceed with HCT,
acknowledging the risk of GVHD, but valuing the potential for cure
higher than the possibility of relapse and risk of GVHD.
WBC indicates white blood cell count; HLA, human leukocyte antigen;
RIC, reduced-intensity conditioning; GVHD, graft-versus-host disease.
Table 2
Case 2
A 46-year-old female presents with symptoms of fatigue. Her spleen is
palpable at the costal margin. Her hemoglobin is 112 g/L, WBC 27 
109/L, and platelets 221  109/L. A smear shows 2% myeloblasts.
Bone marrow examination shows hypercellularity with megakaryocyte
clustering. There is no dysplasia, myeloblasts are <5%, and a reticulin
stain shows grade 2/3 ﬁbrosis. Cytogenetics show del (5q) and
t(1;21). Mutation analysis reveals the JAK2 V617F mutation.
She does not complain of constitutional symptoms or symptoms related
to splenomegaly. She has no siblings; an unrelated donor search
shows 3 potential donors, HLA-matched by high-resolution typing.
Question: How would you treat this patient?
 Proceed with unrelated donor transplantation
 Initiate lenalidomide
 Initiate JAK1/2 inhibitor
 Another option
Discussion: Although the presence of del(5q) suggests that lenalidomide
may be a good option, there are no controlled prospective data in
support of such an approach. She has neither constitutional
symptoms nor signiﬁcant splenomegaly, making a beneﬁt from JAK1/
2 inhibitor treatment unlikely. Her WBC is elevated and myeloblasts
are circulating.
In view of the patient’s young age and the availability of HLA-matched
donors, transplantation should be considered. Recent data indicate
that the success rate with unrelated donors who are HLA matched by
high resolution typing are comparable to those with HLA-identical
siblings.
HLA indicates human leukocyte antigen; WBC, white blood cell count.
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patients, and reported encouraging early results [73]. How-
ever, preliminary results of a prospective multicenter study
from France showed serious adverse events, such as cardio-
genic shock and tumor lysis syndrome, with this approach
[14]. Because of multiple confounding factors, the reasons for
poor results in the French study are not clear. All of the re-
ported data so far are based on small numbers of patients.
Therefore, although theoretically appealing, it will be im-
portant to investigate this approach as part of prospective
studies and at experienced transplantation centers.
There is little indication for the use of JAK1/2 inhibitors
after transplantation, although they could be considered in
patients who relapse (for overall symptom reduction) and,
possibly, in patients with treatment-refractory GVHD.
Although a case can be made for the use of JAK1/2 in-
hibitors as “bridging” therapy before transplantation, other
potential scenarios require further study: (1) administration
of JAK1/2 inhibitors throughout treatment, including after
ASCT; (2) JAK1/2 inhibitors given after transplantationfor control of persistent splenomegaly or constitutional
symptoms; and (3) JAK1/2 inhibitors for GVHD modulation.
The timing of transplantation in patients receiving JAK1/2
inhibitors is a crucial area of further investigation. Some of
the dilemmas related to timing of transplantation in MF are
highlighted in case studies in Tables 1 and 2.
The following questions must be considered: (1) When
should ASCT be performed in patients responding to JAK1/2
inhibition, (2) In patients failing to respond to a given JAK1/2
inhibitors, should one go directly to ASCT or should other,
perhaps investigational, inhibitors be given, and (3) Should
ASCT be carried out as soon as a donor is identiﬁed, re-
gardless of JAK1/2 inhibitor response?
CONCLUSIONS
ASCT has a deﬁnitive role in the treatment of patients
with MF and is the only modality with proven curative po-
tential. However, many patients beneﬁt symptomatically
from treatment with JAK1/2 inhibitors, and there is evidence
that JAK1/2 inhibitors may prolong survival (of patients who
do not undergo transplantation). The impact of treatment
with JAK1/2 inhibitors on ASCT, in particular timing of ASCT,
is not clear and remains an essential area of research. Addi-
tional important questions (eg, sequential use of multiple
inhibitors, combinations of JAK inhibitors and other agents,
selection of 1 JAK inhibitor versus another) will need to be
answered as novel JAK1/2 inhibitors become available.
Whether there is a role for JAK1/2 inhibitors after ASCT re-
mains to be determined. Finally, as JAK2 inhibitors have also
been useful in patients without JAK2 mutations, it will be of
interest to determine how the recent identiﬁcation of CALR
mutations in JAK1-negative patients with MF will impact
treatment decisions.
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